Bin Luo

Assistant Professor

Kennesaw State University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (9)

Purpose: Androgen receptor pathway inhibitors (ARPI), such as enzalutamide and abiraterone, are standard treatments for metastatic castration-resistant prostate cancer (mCRPC). However, a subset of patients display primary resistance and most eventually acquire secondary resistance. This study aimed to define genomic features of ARPI resistance using longitudinal ctDNA analysis. Experimental Design: We used the targeted AR-ctDETECT cell-free DNA (cfDNA) sequencing assay to profile tumor-derived genomic alterations in plasma samples collected at baseline and progression from patients with mCRPC enrolled in the phase III Alliance A031201 trial of first-line enzalutamide with or without abiraterone. Analysis focused on 327 patients with paired samples available from both time points. Results: Progression plasma samples displayed elevated cfDNA levels and increased ctDNA positivity. AR was the most frequently altered gene at baseline and at progression. AR copy-number gains and AR genomic structural rearrangements (AR-GSR) increased at progression, along with copy-number losses of FANCA, POLD1, RAD54L, CDKN2A, ZNRF3, and ETS2. An AR extrachromosomal DNA signature was enriched at progression and was associated with AR-GSRs predicted to truncate the AR ligand-binding domain. Stratification by two extremes of radiographic progression-free survival revealed preferential accumulation of AR alterations in patients with delayed progression and a higher burden of non-AR alterations in patients with rapid progression. Conclusions: AR alterations in ctDNA accumulate at progression in patients with mCRPC treated with ARPIs, especially in those with initially durable responses. These findings support the use of liquid biopsy to serially track resistance mechanisms and inform precision therapy in advanced prostate cancer.

Year:

2026

Year:

2026

PURPOSE In urothelial carcinoma, prior studies have indicated that the basal/squamous molecular subtype and the presence of select DNA damage response (DDR) gene alterations are associated with improved benefit from cisplatin-based chemotherapy. We sought to evaluate these biomarkers in specimens from the phase III Cancer and Leukemia Group B (CALGB) 90601 trial. METHODS We performed whole-transcriptome sequencing (n = 188) and exon capture DNA sequencing (n = 208) on pretreatment tumors from the CALGB 90601 randomized trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with treatment-naïve metastatic bladder cancer. Whole-exome sequencing (WES) was performed on tumors from 22 patients who exhibited rapid progression or durable response. Tumors were assigned to molecular subtypes using three different classifiers. Proportional hazards model was used to correlate molecular subtype with overall survival (OS) and progression-free survival (PFS), adjusting for stratification factors and treatment arm (for PFS). RESULTS Patients with basal tumors had the shortest PFS and OS in the entire cohort. PFS was numerically longer in patients with basal tumors receiving bevacizumab. DDR gene alterations were not associated with improved outcomes. FRY , a candidate predictive biomarker of chemosensitivity identified by WES, did not confer sensitivity to cisplatin or gemcitabine in functional studies. CONCLUSION Molecular subtype and DDR alterations did not correlate with improved outcomes in CALGB 90601. Possible explanations for these results include the small cohort size, lack of strong therapeutic effects of the treatments, genomic heterogeneity between profiled specimens and the metastatic lesions under treatment pressure, and differences in biology associated with different disease states (muscle-invasive v metastatic disease).

Year:

2025

This study addresses the problem of simultaneous variable selection and model estimation in multivariate failure time data, a common challenge in clinical trials with multiple correlated time-to-event endpoints. We propose a unified framework that identifies predictors shared across outcomes, applicable to both low- and high-dimensional settings. For linear marginal hazard models, we develop a penalized pseudo-partial likelihood approach with a group LASSO-type penalty applied to the ℓ2 norms of coefficients corresponding to the same covariates across marginal hazard functions. To capture potential nonlinear effects, we further extend the approach to a sparse-input neural network model with structured group penalties on input-layer weights. Both methods are optimized using a composite gradient descent algorithm combining standard gradient steps with proximal updates. Simulation studies demonstrate that the proposed methods yield superior variable selection and predictive performance compared to traditional and outcome-specific approaches, while remaining robust to violations of the common predictor assumption. In an application to advanced prostate cancer data, the framework identifies both established clinical factors and potentially novel prognostic single-nucleotide polymorphisms for overall and progression-free survival. This work provides a flexible and robust tool for analyzing complex multivariate survival data, with potential utility in prognostic modeling and personalized medicine.

Year:

2025

Multiple imputation (MI) is widely used for handling missing data. However, applying penalized methods after MI can be challenging because variable selection may be inconsistent across imputations. We propose a two-step variable selection method for multiply imputed datasets with survival outcomes: apply LASSO or ALASSO to each MI dataset, followed by ridge regression, and combine estimates using variable selected in any or d% (d = 50, 70, 90, 100) of the MI datasets. For comparison, we also fit stacked MI datasets with weighted penalized regression and a group LASSO approach that enforces consistent selection across imputations. Simulations with Cox models evaluated tuning by AIC, BIC, cross-validation at the minimum error, and the 1SE rule. Across scenarios, performance differed by both the penalization and the selection rule. More conservative choices such as ALASSO with BIC and a 50% inclusion frequency tended to control false positive and gave more stable calibration. The grouped approach achieved comparable selection with modestly higher estimation error. Overall, no single method consistently outperformed others across all scenarios. Our findings suggest that practitioners should weigh trade-offs between selection stability, estimation accuracy, and calibration when applying penalized methods to multiply imputed survival data.

Year:

2025

Year:

2025

Circulating tumor DNA (ctDNA) in plasma cell free DNA (cfDNA) of cancer patients is associated with poor prognosis, but is challenging to detect from low plasma volumes. In metastatic castration-resistant prostate cancer (mCRPC), ctDNA assays are needed to prognosticate outcomes of patients treated with androgen receptor (AR) inhibitors. We develop a custom targeted cfDNA sequencing assay, named AR -ctDETECT, to detect ctDNA in limiting plasma cfDNA available from mCRPC patients in the Alliance A031201 randomized phase 3 trial of enzalutamide with or without abiraterone. Of 776 patients, 59% are ctDNA-positive, with 26% having high ctDNA aneuploidy and 33% having low ctDNA aneuploidy but displaying AR gain or structural rearrangement, MYC / MYCN gain, or a pathogenic mutation. ctDNA-positive patients have significantly worse median overall survival than ctDNA-negative patients (29.0 months vs. 47.4 months, respectively). Here, we show that mCRPC patients identified as ctDNA-positive using the AR -ctDETECT assay have poor survival despite treatment with potent AR inhibitors in a phase 3 trial.

Year:

2024

Year:

2023

Upfront combination therapy in 81 chemotherapy/ARSI-naïve patients with mCRPC was well tolerated with improved PFS.

Year:

2023

Collaborators (10)

Andrew Armstrong

Professor

Duke Cancer Institute

UNITED STATES
View details

Brendan Guercio

Assistant Professor

University of Rochester

UNITED STATES
View details

Henning Reis

Vice Chair (co), Med. Director Molecular Pathology, Professor of Molecular Pathology

University Hospital Essen

GERMANY
View details

Kim Chi

Chief Medical Officer

BC Cancer

CANADA
View details

Luke Gaughan

Reader in Molecular Oncology

Newcastle University

UNITED KINGDOM
View details

Susan Halabi

Duke University

UNITED STATES
View details

Rakesh Heer

Chair of Urology

Imperial College London

UNITED KINGDOM
View details

Scott M Dehm

Faculty, Professor

University of Minnesota

UNITED STATES
View details

Filipe Carvalho

Brigham and Women's Hospital

UNITED STATES
View details

Kevin Kelly

Professor, Associate Director of Research, SKCC

Thomas Jefferson University

UNITED STATES
View details